DOVER, Del., Nov. 4, 2025 /PRNewswire/ -- Eilean Therapeutics LLC, a biopharmaceutical company dedicated to developing best-in-class and first-in-class small-molecule therapies targeting genetic escape mutations in cancer and advancing innovative treatments for chronic inflammatory and immune diseases, today announced the presentation of in vivo data for its first-in-class MALT1 degrader, TE205, as a disease-modifying therapy for ulcerative colitis at the 4th International Conference on Microbiology and Immunology in Las Vegas, Nevada.
Preclinical Findings
In preclinical studies, TE205 demonstrated a robust and multifaceted immunomodulatory effect in the DSS-induced colitis model, achieving both structural and functional restoration of intestinal integrity.
By selectively degrading MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1), TE205 effectively:
- Suppressed NF-κB signaling and pro-inflammatory cytokine production,
- Rebalanced key T-cell and macrophage populations within the lamina propria, and
- Restored epithelial barrier function and mucosal architecture.
Collectively, these results establish TE205 as a potent, first-in-class MALT1 degrader with strong in vivo efficacy and clear disease-modifying potential for inflammatory bowel disease (IBD).
About Eilean Therapeutics
Eilean Therapeutics LLC is a biopharmaceutical company focused on the discovery and development of best-in-class and first-in-class small-molecule therapies addressing genetic and signaling vulnerabilities in hematologic malignancies, solid tumors, and chronic inflammatory diseases.
Leveraging its proprietary AI/ML-driven hybrid drug design platform, Eilean integrates partner datasets, advanced chem-bio modeling, and deep translational expertise to identify high-value molecular targets, accelerate discovery timelines, and advance differentiated, mechanism-based therapies.
Eilean's development-stage pipeline includes:
-
First-in-class MALT1 degraders and best-in-class BTK inhibitors for ulcerative colitis and B-cell malignancies, and
- Selective, wild-type–sparing JAK2 V617F inhibitors for the treatment of myelofibrosis and polycythemia vera.
For more information, please visit www.eileanther.com.
Media Contact:
Amy Burd, PhD
Chief Scientific Officer
Eilean Therapeutics LLC
aburd@eileanther.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/eilean-therapeutics-presents-first-in-class-malt1-degrader-te205-demonstrating-in-vivo-efficacy-in-ulcerative-colitis-at-the-4th-international-conference-on-microbiology-and-immunology-302604708.html
SOURCE Eilean Therapeutics
